AI Drug Discovery
About
Sprintome covers the intersection of artificial intelligence and drug discovery. We track the models, molecules, and methods that are changing how therapeutics are designed — from structure prediction and generative chemistry to automated lab platforms and clinical pipelines.
We built Sprintome because we wanted a single source for this space that respected our time and intelligence. No press-release rewrites. No hype without evidence. Just the developments that matter, explained with enough depth to be useful and enough clarity to be accessible.
Structure prediction
AlphaFold, Boltz, RoseTTAFold, ESMFold — the race to predict protein structure from sequence.
Generative chemistry
Diffusion models, VAEs, and language models designing novel drug candidates.
Computational pipelines
Virtual screening, molecular docking, ADMET prediction — how AI compresses hit-to-lead.
Industry landscape
Xaira, Isomorphic Labs, Recursion, Insilico — funding, partnerships, clinical milestones.
Technical first
We lead with model architecture and validation metrics, not press-release spin.
Signal over noise
We distinguish genuine breakthroughs from incremental improvements.
Accessible depth
We explain computational methods accessibly without dumbing them down.
The right questions
What model? What data? What validation? What clinical impact? Always.
Researchers
Technical deep dives on model architectures, benchmarks, and methods.
Founders & VCs
Company intelligence, funding landscape, and competitive positioning.
Pharma scientists
How AI tools integrate into drug development pipelines.